Georgia's Online Cancer Information Center

Find A Doctor

Sarah Elizabeth Gill MD
Sarah Elizabeth Gill MD
Nancy N. and J.C. Lewis Cancer & Research Pavilion
https://www.sjchs.org/cancer

Sarah Elizabeth Gill MD

Specialty
Gynecology and Gynecologic Oncology
Trial Cancers
Appendix Cancer, Bone and Soft Tissue (including Sarcoma), Brain Cancer , Cervical Cancer, Colon/Rectal Cancer, Endometrial Cancer, Eye Cancer, Gynecologic Cancers, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Quality of Life, Solid Tumor
Education

Medical School: University of Tennessee College of Medicine, Memphis, TN, USA

Residency: Greenville Hospital System, Greenville, SC, USA

Fellowship: Mayo Clinic, Rochester, MN, USA

Active Clinical Trial Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Appendix Cancer

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Bone and Soft Tissue (including Sarcoma)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Brain Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
Cancer Type: Cervical Cancer

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Cancer Type: Cervical Cancer

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Colon/Rectal Cancer

A Four Arm Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combination of Cediranib / Olaparib and the Combination of Olaparib / Wee1 Inhibitor AZD1775 in Women with Recurrent, Persistent or Metastatic Endometrial Cancer (EEC)
Cancer Type: Endometrial Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Cancer Type: Gynecologic Cancers

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Lymphoma

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Multiple Primaries

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Non-Hodgkin Lymphoma

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Solid Tumor

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Unknown Primary

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Unknown Primary
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a state-supported nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education to improve cancer care for Georgians in rural, urban, and suburban communities across the state.